An angiogenic role for the human peptide antibiotic LL-37/hCAP-18

• Published in: The Journal of clinical investigation Vol. 111; no. 11; pp. 1665 - 1672
• Main Authors: Koczulla, Rembert, von Degenfeld, Georges, Kupatt, Christian, Krötz, Florian, Zahler, Stefan, Gloe, Torsten, Issbrücker, Katja, Unterberger, Pia, Zaiou, Mohamed, Lebherz, Corinna, Karl, Alexander, Raake, Philip, Pfosser, Achim, Boekstegers, Peter, Welsch, Ulrich, Hiemstra, Pieter S., Vogelmeier, Claus, Gallo, Richard L., Clauss, Matthias, Bals, Robert
• Format: Journal Article
• Language: English
• Published: American Society for Clinical Investigation 01.06.2003
• ISSN: 0021-9738
• DOI: 10.1172/JCI200317545

Antimicrobial peptides are effector molecules of the innate immune system and contribute to host defense and regulation of inflammation. The human cathelicidin antimicrobial peptide LL-37/hCAP-18 is expressed in leukocytes and epithelial cells and secreted into wound and airway surface fluid. Here we show that LL-37 induces angiogenesis mediated by formyl peptide receptor–like 1 expressed on endothelial cells. Application of LL-37 resulted in neovascularization in the chorioallantoic membrane assay and in a rabbit model of hind-limb ischemia. The peptide directly activates endothelial cells, resulting in increased proliferation and formation of vessel-like structures in cultivated endothelial cells. Decreased vascularization during wound repair in mice deficient for CRAMP, the murine homologue of LL-37/hCAP-18, shows that cathelicidin-mediated angiogenesis is important for cutaneous wound neovascularization in vivo. Taken together, these findings demonstrate that LL-37/hCAP-18 is a multifunctional antimicrobial peptide with a central role in innate immunity by linking host defense and inflammation with angiogenesis and arteriogenesis.